Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
95 articles about Clover Biopharmaceuticals, Inc.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Money on the Move: February 17-23
2/24/2021Life sciences companies across the globe are raking in investment dollars to advance drug programs.
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies
Chinese fusion protein company Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push its COVID-19 vaccine into Phase II/III testing and production planning.
It was a busy week for clinical trial updates. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate - Feb 01, 2021
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover's COVID-19 vaccine candidate and will fund its development through licensure.
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate
Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market
BioSpace Movers & Shakers, Oct. 2
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clover Biopharmaceuticals Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.